# Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections

> **NCT05799716** · PHASE4 · UNKNOWN · sponsor: **Shanghai Changzheng Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Viremia
- Bacteremia
- Acute Rejection of Renal Transplant

## Interventions

- **DRUG:** IVIG

## Key facts

- **NCT ID:** NCT05799716
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-01
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05799716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05799716, "Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05799716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*